表紙
市場調查報告書

細胞治療的全球市場:主要企業配合措施 (2018年)

Global Cell Therapy Market - Companies to Action, 2018

出版商 Frost & Sullivan 商品編碼 808221
出版日期 內容資訊 英文 88 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
細胞治療的全球市場:主要企業配合措施 (2018年) Global Cell Therapy Market - Companies to Action, 2018
出版日期: 2019年03月11日內容資訊: 英文 88 Pages
簡介

以幹細胞、CAR-T細胞、聯合治療為焦點的協同經營模式預計促進全球細胞治療市場成長。

本報告提供全球細胞治療市場與主要企業的配合措施調查,市場定義和概要,細胞治療的價值鏈,供應商的生態系統,主要的等級I、II、III企業的簡介、配合措施等彙整資料。

第1章 摘要整理

第2章 企業與措施 概要

  • 企業與措施:價值的創造者
  • 市場機會及威脅

第3章 細胞治療:市場概要

  • 市場定義
  • 市場區隔
  • 細胞治療的價值鏈
  • 供應商的生態系統
  • 影響者的影響
  • 三大趨勢與供應商策略
  • 細胞治療:供應商環境

第4章 主要企業的簡介:等級I

  • Juno Therapeutics
  • bluebird bio
  • Kite Pharma
  • Adaptimmune
  • Oxford BioMedica
  • JCR 醫藥品
    • 概要
    • 技術平台
    • 聯盟、協定
    • 案例、近幾年的發展等

第5章 主要企業的簡介:等級II

  • Sangamo Therapeutics
  • DiscGenics
  • TiGenix
  • Bone Therapeutics
  • Cell Medica
  • Mesoblast
  • Cynata Therapeutics
  • Medipost
  • Anterogen
  • Pharmicell
    • 企業概要
    • 提供價值

第6章 主要企業的簡介:等級III

  • 數位病理企業的游擊手簡介

第7章 成長機會、推薦行動

  • 生態系統的轉型
  • 成長機會
  • 成長的必要條件

第8章 總論

第9章 附錄

第10章 關於FROST & SULLIVAN

目錄
Product Code: PA16-52

A Collaborative Business Model With Focus on Stem Cells, Chimeric Antigen Receptor T (CAR-T) Cells and Combination Therapies Will Propel Market Growth

The global pharmaceutical industry is continuously evolving. with the rising need for novel therapies in the ever-changing disease landscape. As a result of rising prevalence of chronic infectious diseases as well as continuously growing number of cancer cases, market needs are shifting from traditional, small molecules to novel, large-molecule therapies, with cell therapies dominating the space. The study on the "Global Cell Therapy Market, 2018, Companies to Action” presents an overview of the global cell therapy landscape, with an emphasis on the key game-changing companies disrupting this market. The study highlights the emerging companies across regions that support the development and manufacturing of novel cell therapies.

With the changing market landscape, big pharma and biopharma participants, are looking toward the adoption of a collaborative business approach by either entering into co-development and/or co-commercialization agreements or acquiring smaller, niche participants so as to achieve a competitive advantage with respect to a specific therapy area or technology. The study also delves into some of the leading strategies adopted by market participants in order to succeed in this highly dynamic market. In addition to the above-mentioned strategic analysis, information such as risk sharing and fast to market business models of some of the emerging business models across the cell therapy market is also provided.

Research Highlights:

This study identifies some of the strategies adopted by these game-changing companies with respect to key market-growth opportunities such as the use of combination therapies, manufacturing advancement and automation, adoption of newer gene-editing technologies such as CRISPR/Cas9, and so on. The study also highlights some collaborations and partnerships between these disruptive participants and throws some light on their upcoming drug pipeline; thereby, highlighting their contribution to this market. Additionally, it gives an insight into the leading strategic imperatives shaping the global industry and its long-term implication on market growth.

Key Issues Addressed:

  • What are the key market opportunities in the global cell therapy market?
  • What is the impact of external industry environment on market growth?
  • Which are some of the unique participants that are introducing cutting-edge therapies in this segment?
  • What are the strategic imperatives to be adopted by these participants to bring about this market transformation?
  • What is the growth potential of this rapidly expanding cell therapy market?
  • What are some key factors for success in the global cell therapy market?

Table of Contents

1. EXECUTIVE SUMMARY

  • Key Findings-Analysis of Companies to Action
  • Key Findings-Analysis of Companies to Action (continued)
  • Scope and Segmentation
  • Key Questions Addressed in this Study

2. COMPANIES TO ACTION OVERVIEW

  • Companies to Action Value Creators
  • Opportunities and Threats

3. CELL THERAPY MARKET OVERVIEW

  • Market Definitions
  • Market Segmentation
  • Cell Therapy Value Chain
  • Vendor Ecosystem
  • Impact of Key Market Influencers
  • Top 3 Trends and Vendor Strategies
  • Key Market Participants Aligned with Top 3 Trends
  • Cell Therapy-Vendor Landscape

4. C2A PROFILES-TIER I

  • Juno Therapeutics-Overview
  • Juno Therapeutics-Technology Platforms
  • Juno Therapeutics-Major Partnerships and Agreements
  • bluebird bio-Business Overview
  • bluebird bio-Technology Platform
  • bluebird bio-Major Partnerships and Agreements
  • Kite Pharma-Overview
  • Kite Pharma-Key Technology/ Product/Services
  • Kite Pharma-Case Example and Recent Developments
  • Adaptimmune-Overview
  • Adaptimmune-Technology Platforms
  • Adaptimmune-Case Example and Recent Developments
  • Oxford BioMedica-Overview
  • Oxford BioMedica-Technology Platform
  • Oxford BioMedica-Case Example and Recent Developments
  • JCR Pharmaceuticals-Overview
  • JCR Pharmaceuticals-Technology Platforms
  • JCR Pharmaceuticals-Case Example and Recent Developments

5. C2A PROFILES-TIER II

  • Sangamo Therapeutics-Company Overview
  • Sangamo Therapeutics-Value Proposition
  • DiscGenics-Company Overview
  • DiscGenics-Value Proposition
  • TiGenix-Company Overview
  • TiGenix-Value Proposition
  • Bone Therapeutics-Company Overview
  • Bone Therapeutics-Value Proposition
  • Cell Medica-Company Overview
  • Cell Medica-Value Proposition
  • Mesoblast-Company Overview
  • Mesoblast-Value Proposition
  • Cynata Therapeutics-Company Overview
  • Cynata Therapeutics-Value Proposition
  • Medipost-Company Overview
  • Medipost-Value Proposition
  • Anterogen-Company Overview
  • Anterogen-Value Proposition
  • Pharmicell-Company Overview
  • Pharmicell-Value Proposition

6. C2A PROFILES-TIER III

  • Short Profiles of Digital Pathology Companies
  • Short Profiles of Digital Pathology Companies (continued)
  • Short Profiles of Digital Pathology Companies (continued)
  • Short Profiles of Digital Pathology Companies (continued)

7. GROWTH OPPORTUNITIES AND COMPANIES TO ACTION

  • Transformation in the Industry Ecosystem
  • Five Major Growth Opportunities
  • Strategic Imperatives for Growth

8. THE LAST WORD

  • Conclusion-Key Takeaways
  • Legal Disclaimer

9. APPENDIX

  • Abbreviation List
  • List of Exhibits
  • List of Exhibits (continued)

10. THE FROST & SULLIVAN STORY

  • The Frost & Sullivan Story
  • Value Proposition-Future of Your Company & Career
  • Global Perspective
  • Industry Convergence
  • 360° Research Perspective
  • Implementation Excellence
  • Our Blue Ocean Strategy
Back to Top